ArticleJournal of vaccines & immunization2014
Developing a vaccine for human rhinoviruses.
Article in Journal of vaccines & immunization, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 35 citations in OpenAlex.
- Virus-Specific Impact of Respiratory Viruses on Adult Emergency Department Outcomes.Journal of medical virology · 2026Article
- Epidemiology, Distinct Seasonal Dynamics, and Age-Specific Characteristics of Eight Respiratory Viruses in Thailand, 2025.Journal of tropical medicine · 2026Article
- A synthetic curcumin-like diarylpentanoid analog inhibits rhinovirus infection in H1 hela cells via multiple antiviral mechanisms.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024Article
- Enteroviruses: epidemic potential, challenges and opportunities with vaccines.Journal of biomedical science · 2024Review
- Article
- Toll-like receptor-agonist-based therapies for respiratory viral diseases: thinking outside the cell.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- Identification of Epitopes on Rhinovirus 89 Capsid Proteins Capable of Inducing Neutralizing Antibodies.International journal of molecular sciences · 2022Article
- Neonatal Immune Responses to Respiratory Viruses.Frontiers in immunology · 2022Review
- Early approval of COVID-19 vaccines: Pros and cons.Human vaccines & immunotherapeutics · 2021Review
- Review
- Genotypes of rhinovirus detected among children in two communities of South-West Nigeria.Virus genes · 2021Article
- Mechanisms of Rhinovirus Neutralisation by Antibodies.Viruses · 2021Review
- Human rhinovirus-specific CD8 T cell responses target conserved and unusual epitopes.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021Article
- Vaccine strategies to induce broadly protective immunity to rhinoviruses.Human vaccines & immunotherapeutics · 2020Article
- [Rhinoviruses].Der Internist · 2019Review
- Rhinoviruses and Their Receptors.Chest · 2019Review
- Exploitation of nuclear functions by human rhinovirus, a cytoplasmic RNA virus.PLoS pathogens · 2018Article
- The impact of modifiable risk factor reduction on childhood asthma development.Clinical and translational medicine · 2018Review
- Emerging Respiratory Viruses in Children.Infectious disease clinics of North America · 2018Review
- Novel therapeutic approaches to simultaneously target rhinovirus infection and asthma/COPD pathogenesis.F1000Research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Rhinoviruses (RV's) are common human pathogens of the respiratory tract being the most frequent cause of mild diseases of the upper respiratory tract (common cold) but more importantly they are a major initiator of acute exacerbations of chronic airway diseases. Infections can be life threatening in the latter context however RV -induced common colds have an associated economic cost from loss of productivity due to absence from work or school. There are no appropriate antiviral therapies available and vaccine strategies have failed because of the large number of viral serotypes and the lack of cross-serotype protection generated. Here, approaches past and present for development of a vaccine to these widespread human pathogens are highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.